Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dTwuCduTtWCeukjbCidmzaCicNYAlT
  | Today's Top Story |  |  | | | Health Care & Policy | | | | - Panel suggests ways to avoid clinical trial data gaps
Gaps in clinical trial data can undermine the trials' credibility and are often due to patients' failure to continue compliance because the treatment does not work, causes side effects or is inconvenient, experts say. An expert panel of the National Research Council suggests continuing to follow up on such patients, briefly testing all patients' tolerance for the active drug at the trial's beginning, permitting the use of rescue medications, cutting the length of follow-up periods and targeting groups that do not have many treatment options. HealthDay News (10/3)       - Startup nPharmakon turns drug development upside down
Biotech firm nPharmakon has developed a platform that analyzes molecules for their effect on diseases, rather than identifying a specific disease target. The program retargets molecules whose safety has been proven but which have not proved effective against the target disease. nPharmakon works with drugmakers and has found new targets for about 12 drugs. MedCityNews.com (10/3) | Company & Financial News | | | | - Study finds ways to make biomedical investing more secure
Biomedical firms can use financial techniques such as securitization to raise more-patient capital and increase financial security, researchers report in Nature Biotechnology. The idea is to create megafunds of $5 billion to $15 billion that issue debt and equity securities, and use the proceeds to invest in a vast portfolio of biomedical research projects. Reuters/Felix Salmon blog (10/1), Nature (9/30) - Funding round pulls in $1 million for Pa. maker of ADHD test
BioBehavioral Diagnostics, maker of an FDA-approved test for attention-deficit/hyperactivity disorder, has obtained $1 million in its latest financing round. The funding comes as the Plymouth Meeting, Pa.-based company works to extend reach of its diagnostic device in the U.S. and seek CE mark approval in Europe. MedCityNews.com (10/3) - NIH awards Colby a grant to develop prostate cancer drugs
Colby Pharmaceutical won a Small Business Innovation Research grant from the National Cancer Institute to develop small-molecule novel therapeutics for prostate cancer. The drugs are designed to inhibit interaction between JunD protein and androgen receptor protein. "With this ... award and the recent merger with Othera Pharmaceuticals, Colby is adding to its pipeline of promising ... cancer drug candidates and products for potential partnering," CEO David Zarling said. Pharmaceutical Business Review Online (10/3) | Food & Agriculture | | | | - L.A. Times: Vote no on Calif. biotech labeling law
 California voters should reject the Proposition 37 biotech labeling law, according to the Los Angeles Times. Not only is there no legitimate reason to single out biotech products, but Prop 37 is overly restrictive, sloppily written and burdensome for retailers, according to this editorial. Los Angeles Times (tiered subscription model) (10/4) | Industrial & Environmental | | | | - Drought-resistant elephant grass could be a cellulosic feedstock
Two Department of Agriculture agencies are working on making elephant grass a feedstock for cellulosic ethanol. The Agricultural Research Service and the U.S. Forest Service are searching for new biomass crops. Elephant grass is drought-resistant and will not seed if there is a frost over the winter, which makes it less likely to be invasive in areas where it is grown, said William Anderson, a research geneticist at the ARS Crop Genetics and Breeding Research Unit. EthanolProducer.com (10/3)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | The lure of the distant and the difficult is deceptive. The great opportunity is where you are."
--John Burroughs,
American naturalist and essayist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, October 04, 2012
- Wednesday, October 03, 2012
- Tuesday, October 02, 2012
- Monday, October 01, 2012
- Friday, September 28, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment